Zacks Investment Research
04 Mar 2026, 16:40 UTC · 28w ago
Verdict
Headline leans bullish. We score ESPR +0.20 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.20slightly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Esperion's shares declined 11% following the announcement of the acquisition.
More negative than 81% of claims this week
Esperion Therapeutics entered a definitive agreement to acquire Corstasis Therapeutics for up to $75 million in upfront cash, with potential milestone payments up to $180 million.
Continue reading
5 related stories
More positive than 50% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 64% of claims this week
Esperion plans to fund the acquisition using existing credit facilities and by monetizing its Japanese royalties through Athyrium Capital Management and HealthCare Royalty.
More negative than 67% of claims this week
Which stocks this story touches
More positive than 50% of ticker scores this week
The company is acquiring Corstasis to expand its cardiovascular franchise and accelerate revenue growth, though shares reacted negatively to the news.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
23h ago
+9.3%
Price agrees with the score
$3.18 vs $2.91 close before publication (Mar 3) · not market-adjusted
ESPR chart →
